NASH Treatment Market Accelerates as Rezdiffra and Wegovy Establish Fibrosis-Defined Drug Pathways
核心洞察
The global NASH treatment market is projected to grow from USD 8.75 billion in 2025 to USD 46.87 billion by 2032, expanding at a CAGR of 27.1%.
Madrigal's Rezdiffra, approved in March 2024, created the first dedicated liver-directed prescription pathway for noncirrhotic NASH with moderate-to-advanced fibrosis.
Novo Nordisk's Wegovy gained FDA approval in August 2025 for MASH with F2–F3 fibrosis, connecting liver treatment to established obesity and diabetes care networks.
The global Non-Alcoholic Steatohepatitis (搜索) (NASH) treatment market is entering its first sustained commercial expansion phase, with approved therapies creating defined prescription pathways for patients with moderate-to-advanced liver fibrosis. According to Strategic Market Research, the market was valued at USD 8.75 billion in 2025 and is projected to reach USD 46.87 billion by 2032, expanding at a compound annual growth rate (CAGR) of 27.1% from 2026 to 2032.
The market is increasingly described using the term metabolic dysfunction-associated steatohepatitis (MASH), though NASH remains widely used in physician searches, earlier clinical studies, drug-development programs, payer policies, and patient records. Commercial growth now depends less on overall fatty liver prevalence and more on identifying patients with noncirrhotic MASH or NASH and F2–F3 fibrosis, confirming treatment eligibility, obtaining payer approval, and referring them to hepatology care.
Fibrosis Stage Defines the Commercial Treatment Pool
Approximately 1.3 billion people worldwide were living with metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, with the population projected to approach 1.8 billion by 2050. However, the commercial treatment pool is substantially narrower because current approvals focus on patients with noncirrhotic MASH or NASH and moderate-to-advanced fibrosis.
The U.S. Food and Drug Administration has estimated that approximately 6 million to 8 million Americans have NASH with moderate-to-advanced liver scarring. A separate U.S. disease model projected the number of adults with MASH to rise from 14.9 million in 2020 to 18.4 million by 2030 and 23.2 million by 2050.
Fibrosis stage now determines which patients move from lifestyle management and metabolic-risk monitoring into prescription treatment. Healthcare systems capable of identifying F2–F3 disease through blood-based risk assessment, elastography, imaging, and specialist referral will convert a greater share of underlying prevalence into treated patients.
Rezdiffra Establishes the First Liver-Directed NASH Franchise
Madrigal Pharmaceuticals established the first dedicated U.S. prescription pathway for NASH when the FDA approved Rezdiffra (resmetirom) in March 2024 for adults with noncirrhotic disease and moderate-to-advanced fibrosis. The therapy's once-daily oral dosing gives it a practical position in long-term liver care.
The pivotal MAESTRO-NASH study reported NASH resolution without worsening fibrosis in 25.9% of patients receiving the 80 mg dose and 29.9% receiving the 100 mg dose, compared with 9.7% in the placebo group. At least one-stage fibrosis improvement without worsening steatohepatitis was reported in 24.2% and 25.9% of treated patients, compared with 14.2% receiving placebo.
Madrigal's first-mover position provides an early advantage in specialist awareness and treatment-pathway development. Sustained growth will depend on payer coverage, physician education, noninvasive staging capacity, patient persistence, and the company's ability to defend a liver-directed franchise against therapies already established in metabolic care.
Wegovy Connects MASH Treatment to Obesity and Diabetes Care
The FDA's August 2025 approval of Wegovy (semaglutide 2.4 mg) for adults with MASH and moderate-to-advanced fibrosis changed the competitive structure of the market. Novo Nordisk entered liver treatment with semaglutide already established across obesity, type 2 diabetes, and cardiometabolic care, enabling the company to reach potential MASH patients through endocrinologists, obesity specialists, diabetes clinics, primary-care networks, and cardiovascular-risk programs.
Phase 3 ESSENCE data reported MASH resolution without worsening fibrosis in 62.9% of patients receiving semaglutide 2.4 mg, compared with 34.3% receiving placebo. Fibrosis improvement without worsening MASH occurred in 36.8% of semaglutide-treated patients and 22.4% of the placebo group.
Cross-trial comparisons between Rezdiffra and semaglutide are not appropriate because the studies used different designs, patient populations, treatment durations, and therapeutic mechanisms. Rezdiffra targets liver fibrosis directly, whereas Wegovy combines liver benefits with weight reduction, glycemic control, and broader cardiometabolic management.
Treatment sequencing and combination use could become commercially important. Patients with obesity or diabetes may receive incretin therapy to address metabolic risk, while liver-directed agents may retain an important role for patients requiring fibrosis-focused treatment, those without obesity, or those unable to tolerate GLP-1 therapy.
Diagnostic Infrastructure as a Market Determinant
Low diagnosis rates remain one of the main barriers to pharmaceutical revenue. Published models frequently place NASH diagnosis rates near 10%, with estimates ranging from approximately 3.3% to 14.3%. Many high-risk patients remain in primary care, diabetes clinics, obesity programs, and cardiology practices without a confirmed fibrosis stage.
FIB-4 screening, vibration-controlled transient elastography, liver-stiffness measurement, blood-based fibrosis markers, and specialist referral are becoming part of the treatment value chain. The FDA's consideration of liver-stiffness measurement as a potential surrogate endpoint in MASH trials may also reduce long-term dependence on repeat biopsy, potentially lowering trial costs, improving enrollment, and supporting treatment monitoring.
Late-Stage Pipeline Signals a Multi-Mechanism Future
The availability of approved therapies has not reduced investment in NASH drug development. Competition is expanding across incretin therapies, FGF21 analogues, PPAR agonists, thyroid hormone receptor-beta agonists, glucagon-based combinations, and potential combination regimens.
Eli Lilly's tirzepatide represents one of the most closely watched potential entrants. In the Phase 2 SYNERGY-NASH study, MASH resolution without worsening fibrosis occurred in 44%, 56%, and 62% of patients receiving tirzepatide doses of 5 mg, 10 mg, and 15 mg, respectively, compared with 10% receiving placebo.
Akero Therapeutics is advancing efruxifermin through Phase 3 studies for noncirrhotic MASH and compensated cirrhosis. 89bio is evaluating pegozafermin in Phase 3 programs covering F2–F3 disease and compensated cirrhosis. Inventiva's lanifibranor and Boehringer Ingelheim's survodutide are also progressing through late-stage development.
The category could develop into a segmented treatment ladder rather than a winner-takes-all market. Liver-directed oral therapies, injectable metabolic drugs, FGF21 analogues, and combination regimens may serve different patient profiles and disease stages.
Regional Dynamics Shape Global Access
North America holds the largest share of the NASH treatment market, supported by the first major drug approvals, a large fibrosis-defined patient population, established specialty-pharmacy infrastructure, and broader access to noninvasive liver testing. Payers will heavily influence prescription volumes through prior authorization, fibrosis-stage documentation, specialist requirements, treatment-history reviews, and rules covering lifestyle intervention.
Europe is gaining regulatory momentum, though country-level reimbursement and health-technology assessment decisions will determine how quickly approvals translate into prescription volume. Japan's approval of semaglutide for MASH represents an important Asia-Pacific regulatory milestone, while India follows a different commercial model with saroglitazar already available for NASH and Zydus Lifesciences expanding its reach through agreements with companies including Torrent Pharmaceuticals and Lupin.
Strategic Outlook
The NASH treatment market is becoming a fibrosis-confirmed prescription category rather than a broad fatty-liver market. Competitive leadership will depend on more than positive clinical endpoints. Drug manufacturers must help healthcare providers identify high-risk patients, confirm fibrosis, document payer eligibility, coordinate specialist referrals, initiate treatment, and monitor long-term response.